JOURNAL OF THE CZECH PHARMACEUTICAL SOCIETY AND THE SLOVAK PHARMACEUTICAL SOCIETY

Čes. slov. farm. 2020, 69(3):137-142 | DOI: 10.36290/csf.2020.021

The study of hypoglycemic and hypolipidemic activity of Camelina sativa (L.) Crantz extracts in rats under conditions of high-fructose diet

Tetiana O. Tsykalo1,*, Serhiy D. Trzhetsynskyi2
1 Department of Pharmacognosy, Pharmacology and Botany, Zaporizhzhia State Medical University, Zaporizhzhia, Ukraine
2 Head of the Department of Pharmacognosy, Pharmacology and Botany, Zaporizhzhia State Medical University, Zaporizhzhia, Ukraine

The present article discusses the results of the study of the pharmacological activity of plant extracts from Camelina sativa (L.) Crantz: total herb extract (ECS) and oil from seeds (OCS). ECS was obtained from non-fat raw materials by the method of fractional maceration with 70% ethanol. OCS was obtained by means of extraction in a Soxhlet apparatus. Possible hypoglycemic activity of the extracts and dose selection were evaluated by primary pharmacological screening. Maximum hypoglycemic activity for ECS and OCS at a dose of 200 mg/kg was detected. A deeper study of the hypoglycemic and hypolipidemic properties of the extracts was performed on an experimental model of metabolic syndrome in rats that was induced by excessive doses of fructose (20% solution) for 8 weeks. In the last 2 weeks, the animals additionally received extracts and the reference preparation Metformin® (150 mg/kg). The characteristics of glucose homeo-stasis were evaluated by oral glucose tolerance test and short insulin test. The study also examined the content of total cholesterol and triglycerides. It was found that ECS and OCS of Camelina sativa (L.) Crantz at a dose of 200 mg/kg being administered for 14 days under conditions of high-fructose diet statistically significantly inhibited the formation of glucose tolerance and insulin resistance. ECS was found to have a pronounced lipid-lowering effect on lipid metabolism. The obtained results require further study of this plant raw material.

Keywords: insulin resistance; metabolic syndrome; Camelina sativa (L.) Crantz; glucose tolerance

Received: February 25, 2020; Accepted: April 17, 2020; Published: March 1, 2020  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Tsykalo TO, Trzhetsynskyi SD. The study of hypoglycemic and hypolipidemic activity of Camelina sativa (L.) Crantz extracts in rats under conditions of high-fructose diet. Čes. slov. farm. 2020;69(3):137-142. doi: 10.36290/csf.2020.021.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Alberti K. G. M. M., Zimmet P., Shaw J. Metabolic syndrome - a new worldwide definition. A Consensus Statement from the International Diabetes Federation. Diabet. Med. 2006; 23(5), 469-480. Go to original source... Go to PubMed...
    2. Grundy S. M. Metabolic syndrome pandemic. Arterioscler. Thromb. Vasc. Biol. 2008; 28(4), 629-636. Go to original source... Go to PubMed...
    3. Mishchenko L. A. Metabolic syndrome. Health of Ukraine 2007; 10, 24-25 (in Ukraine).
    4. Vollenweider P., von Eckardstein A., Widmann C. HDLs, Diabetes, and metabolic syndrome. Handbook of Experimental Pharmacology 2014; 224, 405-421. Go to original source... Go to PubMed...
    5. International Diabetes Federation Diabetes Atlas - 8th edition. http://www.diabetesatlas.org (09. 12. 2019).
    6. Governa P., Baini G., Borgonetti V., Cettolin G., Giachetti D., Magnano A. R., Miraldi E., Biagi M. Phytotherapy in the Management of Diabetes. A Review Molecules 2018; 23(1), 105-127. Go to original source... Go to PubMed...
    7. El-Soud N. A, El-Laithy N., El-Saeed G. Antidiabetic activities of Foeniculum vulgare Essential oil in streptozotocin - induced diabetic rats. Macedonian J. Med. Sci. 2011; 4, 139-146.
    8. El-Abhar H. S., Schaalan M. F. Phytotherapy in diabetes: Review on potential mechanistic perspectives. World J. Diabetes 2014; 5(2), 176-197. Go to original source... Go to PubMed...
    9. Kar A., Choudhary B. K., Bandyopadhyay N. G. Comparative evaluation of hypoglycaemic activity of some Indian medicinal plants in alloxan diabetic rats. J Ethnopharmacol. 2003; 84, 105-108. Go to original source... Go to PubMed...
    10. Zhao C., Wu Y. J., Yang C. F., Liu B., Huang Y. F. Hypotensive, hypoglycemic and hypolipidemic effects of bioactive compounds from microalgae and marine microorganisms. International J. of Food Science and Technology 2015; 50(8), 1705-1717. Go to original source...
    11. Shevchenko I. A., Polyakov O. I., Vedmedeva K. V., Komarova I. B. Camelina, Carthamu, Sesamum. Strategy of production of oilseeds in Ukraine (rare crops). Zaporizhzhia; STATUS 2017; 40 p. (in Ukraine).
    12. Kris S., Stuebiger G., Bail S., Unterweger H. Analisis of voliate compounds and triacylglycerol composition of fatty seed oil gained from flax and false flax. European J. of Lipid Science and Technology 2006; 108(1), 48-60. Go to original source...
    13. Demydas G. I., Kvitko H. P., Hetman N. Y. Camelina sativa - oilseed which is alternative to rape ravine in biodiesel production. Proceeding of VNAU 2011; 8(48), 3-8 (in Ukraine).
    14. Shinkovenko I. L., Kashpur N. V., Ilyina T. V., Kovalyova A. M., Goryacha O. V., Koshovyi O. M., Toryanyk E. L., Kryvoruchko O. V. The immunomodulatory activity of the aqueous extract and complexes of biologically active compounds of Galium verum L. herb. Ces. slov. Farm. 2018; 67, 25-29. Go to original source...
    15. Butnariu M., Coradin C. Z. Evaluation of biologically active compounds from Calendula officinalis flowers using spectrophotometry. Chem. Cent. J. 2012; 6(1). Go to original source... Go to PubMed...
    16. Yezerska O., Kalynyuk T., Vronska L. Quantitative determination of hydroxycinnamic acids atic and nonhepatic effects of fructose, fructose-induced inflammation of low gradations. Nutrition problems 2012; 3/4, 12-22 (in Ukraine).
    17. Voloshyna A. A., Kyslychenko V. S., Zhuravel I. O., Burda N. Ye. The study of quantitative content of phenolic compounds in the greater mullein plant material. Ukrainian Journal of Clinical and Laboratory Medicine 2012; 7(4), 202-203 (in Ukraine).
    18. Stefanov A. V. Preclinical studies of drugs. Kyiv: Avicenna 2002; 568 p. (in Ukraine).
    19. Bocarsly M. E., Powell E. S., Avena N. M., Hoebel B. G. High-fructose corn syrup causes characteristics of obesity in rats: increased body weight, body fat and triglyceride levels. Pharmacol. Biochem. Behav. 2010; 97(1), 101-106. Go to original source... Go to PubMed...
    20. Khitan Z., Kim D. H. Fructose: a key factor in the development of metabolic syndrome and hypertension. J. Nutr. Metab. 2013; 2013, 1-12. Go to original source... Go to PubMed...
    21. Klevanova V. S., Trzhetsynskiy S. D. Antidiabetic activity of blood burnet extract in high fructose fed insulin resistant rats. Journal of Pharmacy and Pharmacology 2015; 3, 425-433. Go to original source...
    22. Zalesskij V. N., Velikaya N. V. Molecular and biochemical mechanisms of development of hepatic and nonhepatic effects of fructose, fructose-induced inflammation of low gradations. Nutrition problems 2012; 3/4, 12-22 (in Ukraine).
    23. Buccolo G. Quantitative determination of serum triglyceride by use of enzymes. Clin. Chem. 1973; 5, 476-482. Go to original source...

    Return to the content


    Czech and Slovak Pharmacy

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.